CN117396516A - 抗cea抗体和使用方法 - Google Patents

抗cea抗体和使用方法 Download PDF

Info

Publication number
CN117396516A
CN117396516A CN202280036537.6A CN202280036537A CN117396516A CN 117396516 A CN117396516 A CN 117396516A CN 202280036537 A CN202280036537 A CN 202280036537A CN 117396516 A CN117396516 A CN 117396516A
Authority
CN
China
Prior art keywords
antibody
seq
cea
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280036537.6A
Other languages
English (en)
Chinese (zh)
Inventor
曲亮
李卓
薛柳
刘琦
朱琳
王鹏皓
孙汉资
唐晓燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beigene Guangzhou Biologics Manufacturing Co Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of CN117396516A publication Critical patent/CN117396516A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280036537.6A 2021-05-21 2022-05-18 抗cea抗体和使用方法 Pending CN117396516A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021095113 2021-05-21
CNPCT/CN2021/095113 2021-05-21
CN2022088175 2022-04-21
CNPCT/CN2022/088175 2022-04-21
PCT/CN2022/093566 WO2022242681A1 (en) 2021-05-21 2022-05-18 Anti-cea antibodies and methods of use

Publications (1)

Publication Number Publication Date
CN117396516A true CN117396516A (zh) 2024-01-12

Family

ID=84140248

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280036537.6A Pending CN117396516A (zh) 2021-05-21 2022-05-18 抗cea抗体和使用方法

Country Status (6)

Country Link
US (1) US20240190990A1 (https=)
EP (1) EP4341299A4 (https=)
JP (1) JP2024519078A (https=)
CN (1) CN117396516A (https=)
TW (1) TW202307004A (https=)
WO (1) WO2022242681A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242091A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 针对ceacam5的抗体及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165403A1 (en) * 2023-02-06 2024-08-15 Philogen S.P.A. Anti-cea antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101528013B1 (ko) * 2009-08-31 2015-06-16 로슈 글리카트 아게 친화성-성숙된 인간화된 항-ｃｅａ 단일클론 항체
CN101928347B (zh) * 2010-05-05 2013-03-27 上海海抗中医药科技发展有限公司 抗癌胚抗原抗体及其应用
DK3199552T3 (da) * 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242091A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 针对ceacam5的抗体及其用途

Also Published As

Publication number Publication date
US20240190990A1 (en) 2024-06-13
TW202307004A (zh) 2023-02-16
EP4341299A1 (en) 2024-03-27
EP4341299A4 (en) 2026-01-14
JP2024519078A (ja) 2024-05-08
WO2022242681A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
CN112566935B (zh) 抗ox40抗体和使用方法
AU2017226510B2 (en) A pdl-1 antibody, pharmaceutical composition thereof and use thereof
CA3196933A1 (en) Anti-cd3 antibody and uses thereof
US20240190990A1 (en) Anti-cea antibodies and methods of use
JP2025524386A (ja) 抗ｃｌｄｎ１８．２抗体を含む二重特異性抗体、並びにその医薬組成物及び使用
WO2022242679A1 (en) Anti-cd137 antibodies and methods of use
US20240190989A1 (en) Anti-cea and anti-cd137 multispecific antibodies and methods of use
CN110615840A (zh) 全人源的抗lag-3抗体及其应用
JP2025525916A (ja) 抗ｃｃｒ８抗体及び使用方法
CN114728063B (zh) 用抗ox40抗体和多重激酶抑制剂治疗癌症
CN114641500B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
WO2021098749A1 (en) Methods of cancer treatment with anti-ox40 antibody in combination with radiation
WO2022242682A1 (en) Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
CN120813606A (zh) 抗cldn6抗体和使用方法
WO2025241702A1 (zh) 靶向hla-g的抗体或其抗原结合片段及其应用
HK40109079A (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
CN120917047A (zh) 抗cldn6和抗cd3多特异性抗体及其使用方法
HK40089230A (zh) 药物组合物及用途
CN121057749A (zh) 抗cd3多特异性抗体和使用方法
HK40096798A (zh) 抗cldn18.2抗体、其药物组合物及用途
HK40074321B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
HK40079597A (en) Antibodies binding il4r and uses thereof
BR122024001133A2 (pt) Molécula de anticorpo biespecífica tetravalente e homodimérica

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20251106

Address after: No. 83, Kangyao South Road, Huangpu District, Guangzhou City, Guangdong Province

Applicant after: Guangzhou Baiji Shenzhou biopharmaceutical Co.,Ltd.

Country or region after: China

Address before: 94 sonaris Avenue, kamana Bay, grand caiman, British Isles

Applicant before: BEIGENE, Ltd.

Country or region before: Cayman Islands

TA01 Transfer of patent application right